MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.

Q2 Medicine

Chinese Neurosurgical Journal Pub Date : 2024-07-24 DOI:10.1186/s41016-024-00375-2

Jing Zhang, Xiaoguang Qiu, Jin Feng, Yanwei Liu

{"title":"MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.","authors":"Jing Zhang, Xiaoguang Qiu, Jin Feng, Yanwei Liu","doi":"10.1186/s41016-024-00375-2","DOIUrl":null,"url":null,"abstract":"Background: High-grade gliomas (HGGs) have a rapid relapse and short survival. Studies have identified many clinical characteristics and biomarkers associated with progression-free survival (PFS) and over-survival (OS). However, there has not yet a comprehensive study on survival after the first progression (SAP).Methods: From CGGA and TCGA, 319 and 308 HGGs were confirmed as the first progression. The data on clinical characteristics and biomarkers were analyzed in accordance with OS, PFS, and SAP.Results: Analysis of 319 patients from CGGA, significant predictors of improved OS/PFS/SAP were WHO grade, MGMT promoter methylation, and Ki-67 expression in univariate analysis. Further multivariate analysis showed MGMT promoter methylation and Ki-67 expression were independent predictors. However, an analysis of 308 patients from TCGA found MGMT promoter methylation is the only prognostic marker. A longer SAP was observed in patients with methylated MGMT promoter after standard chemoradiotherapy. In our data, HGGs could be divided into low, intermediate, and high-risk groups for SAP by MGMT methylation and Ki-67 expression.Conclusions: Patients with MGMT promoter methylation have a prolonger SAP after standard chemoradiotherapy. HGGs could be divided into low, intermediate, and high-risk groups for SAP according to MGMT status and Ki-67 expression.","PeriodicalId":36700,"journal":{"name":"Chinese Neurosurgical Journal","volume":"10 1","pages":"24"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267829/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Neurosurgical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s41016-024-00375-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: High-grade gliomas (HGGs) have a rapid relapse and short survival. Studies have identified many clinical characteristics and biomarkers associated with progression-free survival (PFS) and over-survival (OS). However, there has not yet a comprehensive study on survival after the first progression (SAP).

Methods: From CGGA and TCGA, 319 and 308 HGGs were confirmed as the first progression. The data on clinical characteristics and biomarkers were analyzed in accordance with OS, PFS, and SAP.

Results: Analysis of 319 patients from CGGA, significant predictors of improved OS/PFS/SAP were WHO grade, MGMT promoter methylation, and Ki-67 expression in univariate analysis. Further multivariate analysis showed MGMT promoter methylation and Ki-67 expression were independent predictors. However, an analysis of 308 patients from TCGA found MGMT promoter methylation is the only prognostic marker. A longer SAP was observed in patients with methylated MGMT promoter after standard chemoradiotherapy. In our data, HGGs could be divided into low, intermediate, and high-risk groups for SAP by MGMT methylation and Ki-67 expression.

Conclusions: Patients with MGMT promoter methylation have a prolonger SAP after standard chemoradiotherapy. HGGs could be divided into low, intermediate, and high-risk groups for SAP according to MGMT status and Ki-67 expression.

查看原文本刊更多论文

MGMT 启动子甲基化是影响高级别胶质瘤进展后生存的一个强有力的预后因素。

背景：高级别胶质瘤（HGGs）复发快、生存期短。研究发现了许多与无进展生存期（PFS）和超额生存期（OS）相关的临床特征和生物标志物。然而，目前还没有关于首次进展后生存期（SAP）的全面研究：方法：在 CGGA 和 TCGA 中，分别有 319 例和 308 例 HGG 被确认为首次进展。方法：从CGGA和TCGA中分别筛选出319例和308例HGG，根据OS、PFS和SAP分析临床特征和生物标志物数据：结果：对CGGA的319例患者进行分析发现，在单变量分析中，WHO分级、MGMT启动子甲基化和Ki-67表达是改善OS/PFS/SAP的重要预测因素。进一步的多变量分析显示，MGMT 启动子甲基化和 Ki-67 表达是独立的预测因素。然而，对 TCGA 中 308 例患者的分析发现，MGMT 启动子甲基化是唯一的预后标志物。在标准化放疗后，MGMT启动子甲基化的患者SAP较长。在我们的数据中，HGG可根据MGMT甲基化和Ki-67表达情况分为SAP的低、中、高风险组：结论：MGMT启动子甲基化患者在接受标准化放疗后SAP延长。根据MGMT状态和Ki-67表达情况，可将HGG分为SAP的低危、中危和高危组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊